Literature DB >> 15616298

Pharmacodynamic modeling of ciprofloxacin resistance in Staphylococcus aureus.

Jeffrey J Campion1, Patrick J McNamara, Martin E Evans.   

Abstract

Three pharmacodynamic models of increasing complexity, designed for two subpopulations of bacteria with different susceptibilities, were developed to describe and predict the evolution of resistance to ciprofloxacin in Staphylococcus aureus by using pharmacokinetic, viable count, subpopulation, and resistance mechanism data obtained from in vitro system experiments. A two-population model with unique growth and killing rate constants for the ciprofloxacin-susceptible and -resistant subpopulations best described the initial killing and subsequent regrowth patterns observed. The model correctly described the enrichment of subpopulations with low-level resistance in the parent cultures but did not identify a relationship between the time ciprofloxacin concentrations were in the mutant selection window (the interval between the MIC and the mutant prevention concentration) and the enrichment of these subpopulations. The model confirmed the importance of resistant variants to the emergence of resistance by successfully predicting that resistant subpopulations would not emerge when a low-density culture, with a low probability of mutants, was exposed to a clinical dosing regimen or when a high-density culture, with a higher probability of mutants, was exposed to a transient high initial concentration designed to rapidly eradicate low-level resistant grlA mutants. The model, however, did not predict or explain the origin of variants with higher levels of resistance that appeared and became the predominant subpopulation during some experiments or the persistence of susceptible bacteria in other experiments where resistance did not emerge. Continued evaluation of the present two-population pharmacodynamic model and development of alternative models is warranted.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15616298      PMCID: PMC538881          DOI: 10.1128/AAC.49.1.209-219.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics.

Authors:  Y Yano; T Oguma; H Nagata; S Sasaki
Journal:  J Pharm Sci       Date:  1998-10       Impact factor: 3.534

Review 2.  The antibiotic selective process: concentration-specific amplification of low-level resistant populations.

Authors:  F Baquero; M C Negri; M I Morosini; J Blázquez
Journal:  Ciba Found Symp       Date:  1997

3.  Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion.

Authors:  J W Mouton; A A Vinks; N C Punt
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

4.  Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.

Authors:  J Blaser; B B Stone; M C Groner; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

Review 5.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

6.  Comparisons of Staphylococcus aureus grown in vitro or in vivo.

Authors:  D L Watson; J A Prideaux
Journal:  Microbiol Immunol       Date:  1979       Impact factor: 1.955

7.  Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.

Authors:  D N Gilbert; S J Kohlhepp; K A Slama; G Grunkemeier; G Lewis; R J Dworkin; S E Slaughter; J E Leggett
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

8.  Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

Authors:  E Y Ng; M Trucksis; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

9.  Persister cells and tolerance to antimicrobials.

Authors:  Iris Keren; Niilo Kaldalu; Amy Spoering; Yipeng Wang; Kim Lewis
Journal:  FEMS Microbiol Lett       Date:  2004-01-15       Impact factor: 2.742

10.  Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis.

Authors:  G L Drusano; D E Johnson; M Rosen; H C Standiford
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

View more
  24 in total

1.  Mathematical modeling to characterize the inoculum effect.

Authors:  Pratik Bhagunde; Kai-Tai Chang; Renu Singh; Vandana Singh; Kevin W Garey; Michael Nikolaou; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2010-08-30       Impact factor: 5.191

2.  Mechanism-based pharmacodynamic models of fluoroquinolone resistance in Staphylococcus aureus.

Authors:  Philip Chung; Patrick J McNamara; Jeffrey J Campion; Martin E Evans
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  A general model-based design of experiments approach to achieve practical identifiability of pharmacokinetic and pharmacodynamic models.

Authors:  Federico Galvanin; Carlo C Ballan; Massimiliano Barolo; Fabrizio Bezzo
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-06-04       Impact factor: 2.745

4.  Predicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model.

Authors:  Elisabet I Nielsen; Otto Cars; Lena E Friberg
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

5.  Compensation of fitness costs and reversibility of antibiotic resistance mutations.

Authors:  Pia Schulz zur Wiesch; Jan Engelstädter; Sebastian Bonhoeffer
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

6.  Evaluation of pharmacokinetic/pharmacodynamic relationships of PD-0162819, a biotin carboxylase inhibitor representing a new class of antibacterial compounds, using in vitro infection models.

Authors:  Adam Ogden; Michael Kuhn; Michael Dority; Susan Buist; Shawn Mehrens; Tong Zhu; Deqing Xiao; J Richard Miller; Debra Hanna
Journal:  Antimicrob Agents Chemother       Date:  2011-10-10       Impact factor: 5.191

7.  Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients.

Authors:  Matthieu Boisson; Matthieu Jacobs; Nicolas Grégoire; Patrice Gobin; Sandrine Marchand; William Couet; Olivier Mimoz
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

8.  Evolution of ciprofloxacin-resistant Staphylococcus aureus in in vitro pharmacokinetic environments.

Authors:  Jeffrey J Campion; Patrick J McNamara; Martin E Evans
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

9.  Pharmacokinetic-pharmacodynamic model to evaluate intramuscular tetracycline treatment protocols to prevent antimicrobial resistance in pigs.

Authors:  Amais Ahmad; Kaare Græsbøll; Lasse Engbo Christiansen; Nils Toft; Louise Matthews; Søren Saxmose Nielsen
Journal:  Antimicrob Agents Chemother       Date:  2014-12-29       Impact factor: 5.191

10.  Exploring the role of the immune response in preventing antibiotic resistance.

Authors:  Andreas Handel; Elisa Margolis; Bruce R Levin
Journal:  J Theor Biol       Date:  2008-11-08       Impact factor: 2.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.